Current Headlines

  1. Icagen Launches Industry’s Most Comprehensive Research Platform And Services For Sodium Channel Drug Discovery

    Pharmaceutical researchers seeking to discover drug candidates against challenging sodium channel targets can now access the industry’s largest and most advanced collection of sodium channel cell lines and assays through Icagen’s discovery services.

  2. Frontage Doubles Bioanalytical Lab Capacity In USA Due To Increased Demand For Services

    Frontage, a full service contract research organization (CRO) located in the USA and China, is pleased to announce the expansion of its bioanalytical laboratories to meet increased demand for its services from existing and new biopharmaceutical clients

  3. Intersect ENT Announces FDA Submission To Seek Expanded Indication Of PROPEL Mini Steroid Releasing Implant To Treat Patients With Frontal Sinus Disease

    Intersect ENT, Inc., a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, recently announced that the company has submitted a supplemental premarket approval (PMA-s) submission to the U.S

  4. e-Therapeutics: Discovery Platform Exceeding Expectations; Company Focus Now On Commercialisation

    e-Therapeutics plc, the drug discovery and development company, recently announces its half year results for the six months ended 31 July 2015

  5. Osmotica Announces FDA Acceptance Of Filing For Ontinua ER For Alleviation Of Spasticity Resulting From Multiple Sclerosis And Strong Advancement In The Clinical Program For Osmolex ER

    Osmotica Pharmaceutical Corp. (privately held), a global specialty pharmaceutical corporation developing best-in-class therapeutics for the treatment of CNS diseases, announced recently that the New Drug Application (NDA) for OntinuaTM ER has been accepted for filing by the U.S. Food and Drug Administration (FDA)

  6. Sosei Subsidiary Heptares Awarded $5.5M Research & Development Grant From The US National Institute On Drug Abuse

    Sosei Group Corporation is pleased to announce that its wholly-owned subsidiary Heptares Therapeutics (“Heptares”) has been awarded a grant from the National Institute on Drug Abuse (NIDA), one of the US National Institutes of Health

  7. Merck KGaA, Darmstadt, Germany, And Pfizer Announce FDA Orphan Drug Designation For Investigational Immunotherapy Avelumab In Merkel Cell Carcinoma

    Merck KGaA, Darmstadt, Germany, and Pfizer recently announced that the US Food and Drug Administration (FDA) has granted orphan drug designation for the investigational cancer immunotherapy avelumab* for the treatment of Merkel cell carcinoma (MCC), a rare and aggressive type of skin cancer

  8. Crown Bioscience Expands Its Presence In France With Severine Marrony, Ph.D.

    Crown Bioscience, a global drug discovery and development service company providing translational platforms to advance oncology and metabolic disease research, is pleased to announce that Severine Marrony, Ph.D., has joined Crown Bioscience as manager, business development, in France

  9. OncoRx Pharmaceuticals Inc. Announces Treatments For Therapy-Resistant Tumors

    OncoRx Pharmaceuticals, Inc. is announcing its launch as an early-stage pharmaceutical company focused on the development of drug therapies that control the progression of therapy-resistant malignant tumors

  10. University Of Copenhagen (UCPH) And Beckman Coulter Genomics Collaborate (BCG) To Unravel How Mutations Rewire Cancer Cells

    Beckman Coulter Genomics, provider of expert sequencing solutions for research and healthcare institutions worldwide, announces the publishing of studies detailing the early results of the strategic collaboration between Beckman Coulter Genomics (BCG) and the Linding Lab at UCPH, Biotech Research & Innovation Centre (BRIC).